Venture Challenge Alumnus AGILeBiotics contributes to fight against future pandemic infections (e.g. COVID-19)
Today we are reminded that antibiotics are an important part of treatment regiments not only for severe antiviral infections, such as COVID-19, but also other hospitalized patients with multidrug-resistant (MDR) secondary infections. Recent publications by Fei Zhou et al. titled “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan” states that of the patients who died from this infection half (50%) had a secondary bacterial infection leading to sepsis and eventually death. We lack effective treatment of bacterial infections in intensive care units (ICU). Successful treatment of a secondary infections can make the difference between survival and death. Pre-clinical data on AGILeBiotics’ lead compound demonstrate that Toframicin’s activity profile matches the current unmet medical need in the treatment of secondary infections of COVID-19 patients. Venture Challenge Alumnus AGILeBiotics has now appointed Victor Schut as CEO and co-founder Dr. Andreas A. Bastian has taken on the role of Chief Operating Officer (COO). Please see attached press release. Currently raising Series A investment, the appointments come in line with the company’s plans and development strategy. AGILeBiotics is among a few biotech companies focusing on the development of novel antibiotics for the treatment of severe MDR bacterial infections. Its lead compound,Toframicin, is a novel ultra-broad-spectrum antibiotic with improved safety profile and amplified efficacy against WHO’s priority pathogens, i.e. bacterial ESKAPE panel, pathogens which not only cause secondary infections, as observed in COVID-19 patients, but in general high death rate infections, such as respiratory infections, i.e. hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), bloodstream infections (BSI) and sepsis. Thanks to Toframicin’s ultra-broad-spectrum activity, currently also other indications are being explored, e.g. cystic fibrosis-associated P. aeruginosa and non-tuberculosis Mycobacterium (NTM) infections.